INFECTION ANALYSIS DEVICE AND METHOD

Description of the Invention

The infection analysis device is a biosensor that enables the detection of infections caused by pathogens using biological samples taken from the human body (such as blood, urine, etc.). The device and method allow for the analysis of a blood sample by dropping it onto a test strip, providing results in a very short time.



Applicant

Aksense Medikal Biyoteknoloji Arge San. ve Tic. A.Ş.



Inventor

Asiye Karakullukçu

Country/Region	Application Number	Status
European Patent	EP2020085859	Under Review
United Kingdom	GB2592887B	Granted
Chinese	CN115244399A	Under Review
USA	US2023027745A1	Under Review

Benefits

- Provides effective treatment by enabling the rapid detection of infection-related diseases, preventing cases and patient losses.
- Reduces the infection detection time, which can take up to 48 hours with traditional methods, to just 1 minute, allowing for quick analysis.
- Offers accurate analysis by enabling the detection of pathogens causing infections through multi-scan capabilities.

Areas of Use

The infection analysis system is suitable for hospitals, clinics, health checkpoints, home care services and personal use.

Market Information

The Point-of-Care (PoC) diagnostics market is projected to reach \$75.5 billion by 2027, growing at a CAGR of 10.7%. One of the key areas where PoC diagnostic methods are used, infectious diseases, is expected to see the PoC diagnostics market reach \$4.22 billion by 2028, with the Asian market considered to have high potential.

Target Market

The target audience can include hospitals, clinical research centers and individual users, particularly those operating under the specified NACE codes.



Nace Code	Activity Definition	
72.11.01	Research and experimental development activities related to biotechnology	

Commercialization Expectation

It is intended to transfer technology to the firms identified as the target audience through patent licensing or assignment. This technology transfer will be supported by industry-industry collaboration projects. Since it is an internationally patented invention, it qualifies for TÜBİTAK's 1702 Patent-Based Technology Transfer Support Program. If a potential technology transfer is included under this program, the client organization can recover 25% to 65% of the costs paid for the patent.

Contact +90 212 691 60 01 kulucka@entertech.com.tr

